Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COLL Collegium Pharmaceutical	$27.00 -2.2%	$28.30	$23.23 ▼ $42.29	$867.56M	0.76	442,564 shs	232,582 shs
DRUG Bright Minds Biosciences	$30.70 -0.6%	$33.54	$0.93 ▼ $79.02	$216.25M	-5.5	823,967 shs	39,140 shs
PHVS Pharvaris	$18.48 +7.0%	$15.00	$11.51 ▼ $25.50	$966.32M	-2.84	73,753 shs	145,741 shs
SYRE Spyre Therapeutics	$15.23 +1.4%	$16.15	$10.91 ▼ $40.49	$918.00M	3.05	599,877 shs	439,457 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COLL Collegium Pharmaceutical	+2.72%	+2.64%	-7.10%	-14.87%	-24.82%
DRUG Bright Minds Biosciences	-4.01%	-7.79%	-15.37%	+3.45%	+2,747.00%
PHVS Pharvaris	+1.23%	+14.45%	+9.30%	-2.10%	-26.35%
SYRE Spyre Therapeutics	+2.39%	+7.59%	-16.28%	-31.42%	-56.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COLL Collegium Pharmaceutical	4.0483 of 5 stars	3.4	1.0	3.0	2.9	0.8	2.5
DRUG Bright Minds Biosciences	3.309 of 5 stars	3.6	5.0	0.0	3.6	2.5	0.0
PHVS Pharvaris	2.1947 of 5 stars	3.5	3.0	0.0	3.3	0.8	0.0
SYRE Spyre Therapeutics	1.7938 of 5 stars	3.6	0.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COLL Collegium Pharmaceutical	2.80	Moderate Buy	$43.60	61.48% Upside
DRUG Bright Minds Biosciences	3.20	Buy	$84.33	174.70% Upside
PHVS Pharvaris	3.00	Buy	$39.00	111.04% Upside
SYRE Spyre Therapeutics	3.20	Buy	$49.57	225.49% Upside

Current Analyst Ratings Breakdown

Latest DRUG, COLL, PHVS, and SYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/29/2025	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$28.00
4/9/2025	COLL Collegium Pharmaceutical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
4/8/2025	SYRE Spyre Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/8/2025	SYRE Spyre Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
3/24/2025	COLL Collegium Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/18/2025	SYRE Spyre Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
2/19/2025	DRUG Bright Minds Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$85.00 ➝ $85.00
2/18/2025	SYRE Spyre Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
2/4/2025	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$37.00 ➝ $36.00
1/31/2025	PHVS Pharvaris	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$46.00 ➝ $55.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COLL Collegium Pharmaceutical	$631.45M	1.37	$9.78 per share	2.76	$5.99 per share	4.51
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$5.86 per share	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	$7.95 per share	N/A
SYRE Spyre Therapeutics	$890K	1,031.46	N/A	N/A	($0.22) per share	-69.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COLL Collegium Pharmaceutical	$48.15M	$1.86	11.64	4.49	N/A	14.78%	104.67%	18.38%	5/8/2025 (Estimated)
DRUG Bright Minds Biosciences	-$2.06M	-$0.17	N/A	N/A	N/A	N/A	-5.85%	-5.68%	5/21/2025 (Estimated)
PHVS Pharvaris	-$109.18M	-$2.68	N/A	N/A	N/A	N/A	-38.52%	-36.69%	5/14/2025 (Estimated)
SYRE Spyre Therapeutics	-$338.79M	-$4.23	N/A	N/A	N/A	N/A	-210.01%	-44.40%	5/8/2025 (Estimated)

Latest DRUG, COLL, PHVS, and SYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	N/A	DRUG Bright Minds Biosciences	-$0.38	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	PHVS Pharvaris	-$0.80	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	N/A	N/A	N/A	$174.96 million	N/A
5/8/2025	Q1 2025	SYRE Spyre Therapeutics	-$0.74	N/A	N/A	N/A	N/A	N/A
4/7/2025	Q4 2024	PHVS Pharvaris	-$0.74	-$0.68	+$0.06	-$0.68	N/A	N/A
2/27/2025	Q4 2024	COLL Collegium Pharmaceutical	$1.54	$1.63	+$0.09	$0.36	$179.68 million	$181.95 million
2/27/2025	Q4 2024	SYRE Spyre Therapeutics	-$0.89	-$0.81	+$0.08	-$0.81	$2.10 million	N/A
2/13/2025	Q1 2025	DRUG Bright Minds Biosciences	-$0.23	$0.01	+$0.24	$0.01	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COLL Collegium Pharmaceutical	3.43	0.97	0.88
DRUG Bright Minds Biosciences	N/A	126.01	11.31
PHVS Pharvaris	N/A	19.08	19.08
SYRE Spyre Therapeutics	N/A	7.32	7.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COLL Collegium Pharmaceutical	N/A
DRUG Bright Minds Biosciences	40.52%
PHVS Pharvaris	N/A
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
COLL Collegium Pharmaceutical	2.51%
DRUG Bright Minds Biosciences	42.66%
PHVS Pharvaris	11.84%
SYRE Spyre Therapeutics	6.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	30.97 million	Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
PHVS Pharvaris	30	52.29 million	46.10 million	Not Optionable
SYRE Spyre Therapeutics	100	60.28 million	48.24 million	Optionable

DRUG, COLL, PHVS, and SYRE Headlines

Recent News About These Companies

Adage Capital Partners GP L.L.C. Lowers Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 28 at 5:37 AM | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Trading Down 3.6% - Here's Why

April 24, 2025 | marketbeat.com

Capital World Investors Invests $8.81 Million in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 24, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Trading Up 6.3% - Still a Buy?

April 23, 2025 | marketbeat.com

B Group Inc. Buys Shares of 50,000 Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 23, 2025 | marketbeat.com

Geode Capital Management LLC Buys 75,081 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 21, 2025 | marketbeat.com

Affinity Asset Advisors LLC Purchases 325,908 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 17, 2025 | marketbeat.com

Fmr LLC Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 15, 2025 | marketbeat.com

Why Spyre Therapeutics, Inc.’s (SYRE) Stock Is Up 6.55%

April 14, 2025 | aaii.com

F M Investments LLC Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 14, 2025 | marketbeat.com

Vanguard Group Inc. Buys 330,553 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 13, 2025 | marketbeat.com

What is Leerink Partnrs' Estimate for SYRE Q1 Earnings?

April 12, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Upgraded to "Strong-Buy" at Leerink Partnrs

April 11, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Now Covered by Leerink Partners

April 10, 2025 | marketbeat.com

Spyre Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:SYRE | Benzinga

April 9, 2025 | benzinga.com

Spyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year Low - Here's What Happened

April 9, 2025 | marketbeat.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Recommendation of "Buy" from Analysts

April 9, 2025 | marketbeat.com

Leerink Partners Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform Recommendation

April 8, 2025 | msn.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Wellington Management Group LLP

April 8, 2025 | marketbeat.com

Schroder Investment Management Group Takes $2.56 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 8, 2025 | marketbeat.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Holdings Lowered by Cinctive Capital Management LP

April 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
By Nathan Reiff | April 1, 2025
View D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
3 Momentum Stocks That Could Soar Post-Market Volatility
By Nathan Reiff | April 21, 2025
View 3 Momentum Stocks That Could Soar Post-Market Volatility
3 Stocks Presenting Generational Buying Opportunities
By Chris Markoch | April 25, 2025
View 3 Stocks Presenting Generational Buying Opportunities
Viking Therapeutics Stock Pops But Struggles to Hold Gains
By Chris Markoch | April 16, 2025
View Viking Therapeutics Stock Pops But Struggles to Hold Gains
Can Solid Biosciences Challenge Sarepta in the DMD Market?
By Leo Miller | April 8, 2025
View Can Solid Biosciences Challenge Sarepta in the DMD Market?

DRUG, COLL, PHVS, and SYRE Company Descriptions

Collegium Pharmaceutical NASDAQ:COLL

$27.00 -0.60 (-2.17%)

As of 04:00 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Bright Minds Biosciences NASDAQ:DRUG

$30.70 -0.19 (-0.62%)

As of 04:00 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Pharvaris NASDAQ:PHVS

$18.48 +1.21 (+7.01%)

As of 04:00 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Spyre Therapeutics NASDAQ:SYRE

$15.23 +0.21 (+1.40%)

As of 04:00 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time